Phase II study of paclitaxel in pretreated advanced gastric cancer
Phase II study of paclitaxel in pretreated advanced gastric cancer
复制标题
DOI：
10.1097/00001813-199804000-00003
复制
发表时间：
1998-04-01
影响因子：
2.3
通讯作者：
Catalano, G
中科院分区：
文献类型：
--
作者：
Cascinu, S;Graziano, F;Catalano, G
晚期胃癌患者在PELF化疗（5-氟尿嘧啶、亚叶酸素、顺铂、epidororbicin）后无反应或进展，给予紫杉醇225 mg/m(2)，每3周输注3小时。36名患者参加了这项研究，所有患者的反应和毒性均可评估。毒性较轻：除脱发外，3级毒性为6例白细胞减少和血小板减少，2级神经毒性为7例。8名患者（22.2%,95% CI: 9-35%）获得客观缓解，中位持续时间为5个月。所有患者的中位生存时间为8个月。36例患者中有16例（44%）经治疗后症状明显缓解。对一线化疗难治性晚期胃癌患者，门诊紫杉醇给予超过3小时的补救性治疗可能有效。[C] 1998 Lippincott-Raven出版社。
Patients with advanced gastric cancer unresponsive or progressing after PELF chemotherapy (5-fluorouracil, leucovorin, cisplatin and epidoxorubicin) received paclitaxel at the dose of 225 mg/m(2) every 3 weeks, over 3 h infusion. Thirty-six patients entered the study, and all of them were evaluable for response and toxicity. Toxicity was mild: apart from alopecia, grade 3 toxicities were leukopenia and thrombocytopenia in six patients, and grade 2 neurotoxicity in seven patients. Eight patients (22.2%, 95% CI: 9-35%) achieved an objective response, with a median duration of 5 months. Median survival time for all patients was 8 months. In 16 of 36 patients (44%), treatment determined a significant relief of symptoms. Out-patient paclitaxel given over 3 h may be effective as salvage treatment in patients with advanced gastric cancer refractory to first line chemotherapy. [(C) 1998 Lippincott-Raven Publishers.].